432 filings
Page 5 of 22
8-K
8ad6739
30 Mar 22
Soleno Therapeutics Announces Pricing of Approximately $15 Million Underwritten Public Offering
5:24pm
424B5
egc2xv
30 Mar 22
Prospectus supplement for primary offering
5:21pm
8-K
f9dr64 eehgevnjft0
28 Mar 22
Soleno Therapeutics Announces Proposed Underwritten Public Offering
4:59pm
424B5
xjxx6hmqvq g884aod3
28 Mar 22
Prospectus supplement for primary offering
4:53pm
8-K
ff6ks9d8f74tnz8tn20
18 Mar 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:05pm
8-K
r9gqzq48z6g9zzzyfbb
31 Jan 22
Departure of Directors or Certain Officers
4:00pm
8-K
rz4vbvf8refj4
24 Jan 22
Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome
8:06am
8-K
fdok61v
30 Dec 21
Entry into a Material Definitive Agreement
4:37pm
8-K
k3uewzmy6
10 Nov 21
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2021 Financial Results
4:16pm
8-K
s8zf2l adu
17 Sep 21
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:31pm
8-K
goh9yvhjwpx xw27mo
28 Jul 21
Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2021 Financial Results
4:06pm
8-K
h1ieu2d8xcdccnha3
16 Jul 21
Entry into a Material Definitive Agreement
4:14pm
424B5
nw4lv
16 Jul 21
Prospectus supplement for primary offering
4:07pm
8-K/A
040mhixd
16 Jun 21
Submission of Matters to a Vote of Security Holders
6:05am
8-K
u6l04r
3 Jun 21
Submission of Matters to a Vote of Security Holders
4:05pm
8-K
k25uq
5 May 21
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2021 Financial Results
4:01pm